Related Experiment Video
Updated: Jul 19, 2026
12:21
Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
Published on: November 27, 2016
Serotonin and norepinephrine transporter binding profile of SSRIs
David A Gutman1, Michael J Owens
1Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA.
Essential Psychopharmacology
|September 23, 2006
Summary
Current antidepressant medications enhance monoamine activity, primarily by blocking serotonin and norepinephrine transporters. Selective or combined transporter inhibition efficacy requires further empirical investigation.
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Background:
- Mood disorder pharmacotherapy relies on 1950s-1960s findings linking monoamine enhancement to antidepressant effects.
- Effective antidepressants increase postsynaptic serotonin transmission and often affect central noradrenergic activity.
- Most antidepressants function by blocking serotonin transporter (SERT) or norepinephrine transporter (NET) activity.
Purpose of the Study:
- To evaluate the efficacy and tolerability of selective versus multi-transporter inhibiting antidepressants.
- To explore the rationale behind combined SERT and NET inhibition for improved antidepressant efficacy.
Main Methods:
- Review of preclinical studies on long-term antidepressant administration.
- Analysis of drug mechanisms targeting SERT and NET.
- Consideration of empirical studies to determine efficacy of combined transporter inhibition.
Main Results:
- Long-term antidepressant use enhances postsynaptic serotonin transmission.
- Selective transporter inhibitors show effectiveness and tolerability.
- Multi-transporter agents may not offer superior efficacy and could increase adverse events.
Conclusions:
- Antidepressant efficacy is linked to modulation of monoamine transporters, particularly SERT and NET.
- The potential for enhanced efficacy with combined SERT and NET blockade needs empirical validation.
- Further research is necessary to confirm the benefits of dual-action antidepressants.
More Related Videos
Related Concept Videos
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:21G-protein Coupled Receptors
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.